Treatment with biologic therapies and the risk of cancer in patients with IBD

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 4, Issue 2, 2007, Pages 78-91

  Biancone, Livia ^a   Calabrese, Emma ^a   Petruzziello, Carmelina ^a   Pallone, Francesco ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; CERTOLIZUMAB PEGOL; ETANERCEPT; GLUCOCORTICOID; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; METRONIDAZOLE; NARCOTIC ANALGESIC AGENT; NATALIZUMAB; ONERCEPT; PLACEBO; PREDNISONE; STEROID; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIINFLAMMATORY AGENT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; ANUS CARCINOMA; BILE DUCT CARCINOMA; BIOLOGICAL THERAPY; BLADDER CANCER; BLADDER CARCINOMA; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CHRONIC DISEASE; CHRONIC INFLAMMATION; CLINICAL TRIAL; COLON ADENOCARCINOMA; CROHN DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; LARYNX CANCER; LEUKEMIA; LUNG CANCER; LYMPHOMA; MAINTENANCE THERAPY; PATIENT SELECTION; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PSORIASIS; PSORIATIC ARTHRITIS; RECTUM CARCINOMA; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; SKIN CANCER; ULCERATIVE COLITIS; ADULT; AGED; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; FEMALE; MALE; MIDDLE AGED; NEOPLASM; RISK FACTOR;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; NEOPLASMS; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33847731814     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep0695     Document Type: Review

References (77)

1. Fiocchi C (1998) Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology 115: 182-205
2. MacDonald TT and Monteleone G (2005) Immunity, inflammation, and allergy in the gut. Science 307: 1920-1925
3. Knight DM et al. (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30: 1443-1453
4. Hanauer SB (2003). Crohn's disease: Step up or top down therapy. Best Pract Res Clin Gastroenterol 17:131-137
5. Hanauer SB (2005) Top-down versus step-up approaches to chronic inflammatory bowel disease: Presumed innocent or presumed guilty. [Editorial] Nat Clin Pract Gastroenterol Hepatol 2: 493
6. Fiocchi C (2004) Closing fistulas in Crohn's disease - should the accent be on maintenance or safety? N Engl J Med 350: 934-936
7. Munkholm P et al. (1993) Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 105: 1716-1723
8. van Dullemen HM et al. (1995) Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109: 129-135
9. Targan SR et al. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 337: 1029-1035
10. Rutgeerts P et al. (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117: 761-769
11. Present DH et al. (1999) Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340: 1398-1405
12. Hanauer SB et al. (2002) Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 359: 1541-1549
13. Rutgeerts P et al. (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126: 402-413
14. Sands BE et al. (2004) Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350: 876-885
15. Kinney T et al. (2003) Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: Clinical experience with 400 infusions. Am J Gastroenterol 98: 608-612
16. Colombel JF et al. (2004) The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients. Gastroenterology 126: 19-31
17. Ljung et al. (2004) Infliximab in inflammatory bowel disease: Clinical outcome in a population-based cohort from Stockholm County. Gut 53: 849-853
18. Sandborn WJ and Loftus EV (2004) Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut 53: 780-782
19. Biancone L et al. (2006) Infliximab and newly diagnosed neoplasia in Crohn's disease: A multicentre matched pair study. Gut 55: 228-233
20. Orlando A et al. (2005) Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. Dig Liver Dis 37: 577-583
21. Persson PG et al. (1994) Crohn's disease and cancer: A population-based cohort study. Gastroenterology 107: 1675-1679
22. Bickston SJ et al. (1999) The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology 117: 1433-1437
23. Alcain G et al. (2003) Acute leukemia after infliximab therapy. Am J Gastroenterol 98: 2577
24. Losco A et al. (2004) Epstein-Barr virus-associated lymphoma in Crohn's disease. Inflamm Bowel Dis 10: 425-429
25. Bucher C et al. (2005) Biologics in inflammatory disease: Infliximab associated risk of lymphoma development. Gut 54: 732-733
26. Nicholson T et al. (2005) Crohn's colitis presenting with node-negative colon cancer and liver metastasis after therapy with infliximab: Report of two cases. Dis Colon Rectum 48: 1651-1655
27. Al-Za'abi AM et al. (2005) Eruptive tufted angiomas in a patient with Crohn's disease. J Clin Pathol 58: 214-216
28. Zagoni T et al. (2005) Carcinoma arising in enterocutan fistulae of Crohn's disease patients: Description of two cases. Int J Colorectal Dis 21: 461-464
29. Peyrin-Biroulet L et al. (2006) Colon cancer after infliximab therapy for Crohn's disease in a young patient transplanted for primary sclerosing cholangitis. Gut 101: 2664-2665
30. Podolsky DK et al. (2006) A 71-year old woman with Crohns' disease and altered mental status. N Engl J Med 354: 1178-1184
31. Lewis JD et al. (2001). Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 121: 1080-1087
32. Loftus VE and Sandborn W (2001) Lymphoma risk in inflammatory bowel disease: Influences of referral bias and therapy. Gastroenterology 121: 1239-1242
33. Brown SL et al. (2002) Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 46: 3151-3158
34. Parsi MA and Lashner BA (2004) Safety of infliximab: Primum non nocere. The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients. Inflamm Bowel Dis 10: 486-487
35. Rutgeerts P et al. (2006) Review article: Infliximab therapy for inflammatory bowel disease - seven years on. Aliment Pharmacol Ther 23: 451-463
36. Chang JT and Lichtenstein GR (2006) Drug insight: Antagonists of tumor-necrosis factor-α in the treatment of inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 3: 220-228
37. Periodic Safety Update Report (PSUR 11) (2005) Infliximab
38. Lichtenstein GR et al. (2006) Serious infections and mortality in association with therapies for Crohn's disease: TREAT Registry. Clin Gastroenterol Hepatol 4: 621-630
39. Siegel CA et al. (2006) Risk and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol 4: 1017-1024
40. Centocor [http://www.centocor.com/index.jsp]
41. Chey WY et al. (2001) Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis 7 (Suppl): S30-S33
42. Sands BE et al. (2001) Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study. Inflamm Bowel Dis 7: 83-88
43. Kaser A et al. (2001) Infliximab in severe steroid-refractory ulcerative colitis: A pilot study. Wien Klin Wochenschr 113: 930-933
44. Kohn A et al. (2002) Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: Result of an open study on 13 patients. Dig Liver Dis 34: 626-630
45. Actis GC et al. (2002) Infliximab for treatment of steroid-refractory ulcerative colitis. Dig Liver Dis 34: 631-634
46. Probert CSJ et al. (2003) Infliximab in moderately severe glucorticoid resistant ulcerative colitis: A randomised controlled trial. Gut 52: 998-1002
47. Ochsenkuhn T et al. (2004) Infliximab for acute, not steroid-refractory ulcerative colitis: A randomized pilot study. Eur J Gastroenterol Hepatol 16: 1167-1171
48. Järnerot G et al. (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study. Gastroenterology 128: 1805-1811
49. Rutgeerts P et al. (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 2462-2476
50. Su C et al. (2002) Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 97: 2577-2584
51. National Cancer Institute. Surveillance, Epidemiology, and End Results Database (SEER) program. SEER Incidence Crude Rates, 11 Registries, 1993-2001 [http://seer.cancer.gov/] (accessed 28 November 2006)
52. Szlosarek PW et al. (2006) Expression and regulation of tumour necrosis factor alpha in normal and malignant ovarian epithelium. Mol Cancer Ther 5: 382-390
53. Germanidis G et al. (2005) Regression of inflammatory myofibroblastic tumour of the gastrointestinal tract under infliximab treatment. Dig Dis Sci 50: 262-265
54. Jatoi A et al. (2004) A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients. Support Care Cancer 12: 859-863
55. Couriel D et al. (2004) Tumor necrosis factor-alpha blockade for the treatment for the treatment of acute GVHD. Blood 104: 649-654
56. Stack WA et al. (1997) Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 349: 521-524
57. Sandborn WJ et al. (2001) An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial. Gastroenterology 120: 1330-1338
58. Sandborn WJ et al. (2004) CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: A randomised, double-blind, placebo-controlled trial. Gut 53: 1485-1493
59. Feagan BG et al. (2005) A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther 21: 373-384
60. Feagan BG et al. (2006) CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: A randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 23: 617-628
61. D'Haens G et al. (2001) Etanercept in the treatment of active refractory Crohn's disease: A single-center pilot study. Am J Gastroenterol 96: 2564-2568
62. Sandborn WJ et al. (2001) Etanercept for active Crohn's disease: A randomized, double-blind placebo-controlled trial. Gastroenterology 121: 1089-1094
63. Rutgeerts P et al. (2003) Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): Results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 17: 185-192
64. Rutgeerts P et al. (2006) Onercept for moderate-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4: 888-893
65. Sandborn WJ et al. (2004) An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 99: 1984-1989
66. Youdim A et al. (2004) A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 10: 333-338
67. Papadakis KA et al. (2005) Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 100: 75-79
68. Hanauer S et al. (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-1 trial. Gastroenterology 130: 323-333
69. Winter TA et al. (2004) Intravenous CDP870, a PEGylated Fab'fragment of a humanized anti-tumor necrosis factor antibody, in patients with moderate-to severe Crohn's disease: An exploratory study. Aliment Pharmacol Ther 20: 1337-1346
70. Schreiber S et al. (2005) A randomized, placebo-controlled trial of certulizumab pegol (CDP870) for treatment of Crohns' disease. Gastroenterology 129: 807-818
71. Shen C et al. (2005) Adalimumab induces apoptosis of human monocytes: A comparative study with infliximab and etanercept. Aliment Pharmacol Ther 21: 251-258
72. Scheinfeld N et al. (2004) A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatol Treat 15: 280-294
73. Hanauer S (2004) Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Overview of randomized clinical studies. Rev Gastroenterol Disord 4 (Suppl): S18-S24
74. Bongartz T et al. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275-2285
75. Gordon FH et al. (2001) A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease. Gastroenterology 121: 268-274
76. Ghosh S et al. (2003) Natalizumab for active Crohn's disease. N Engl J Med 348: 24-32
77. Sandborn WJ et al. (2005) Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353: 1912-1925